A Case of Pathologic Complete Response Achieved with Preoperative Pembrolizumab Therapy for Transverse Colon Cancer
A 77-year-old female patient presented with a medical history of 4 cancerous lesions, each with a surgical history. She was referred to our hospital due to anemia. Upon examination, she was diagnosed with transverse colon cancer. Duodenal invasion was suspected, which made performing R0 surgery difficult; therefore, the NAC approach was chosen. Three courses of CAPOX were administered, resulting in tumor obstruction, leading to the formation of an ileum stoma. MSI testing revealed MSI-H, and pembrolizumab treatment was initiated. CT scans showed tumor shrinkage, and PET scans indicated no accumulation, resulting in a cCR. Colon resection including the lesion suspected of stenosis was performed with a strong desire for stoma closure and the determination of potential curative resection. Additionally, a partial resection of the duodenum was performed. Pathological examination did not reveal any evident tumor cells, leading to the determination for a pCR. The patient has been under postoperative surveillance for 1 year without any recurrence.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Gan to kagaku ryoho. Cancer & chemotherapy - 50(2023), 13 vom: 02. Dez., Seite 1612-1614 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Akazawa, Yo [VerfasserIn] |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 05.02.2024 Date Revised 05.02.2024 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM367927241 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367927241 | ||
| 003 | DE-627 | ||
| 005 | 20240205232123.0 | ||
| 007 | tu | ||
| 008 | 240202s2023 xx ||||| 00| ||jpn c | ||
| 028 | 5 | 2 | |a pubmed24n1281.xml |
| 035 | |a (DE-627)NLM367927241 | ||
| 035 | |a (NLM)38303358 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Akazawa, Yo |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Case of Pathologic Complete Response Achieved with Preoperative Pembrolizumab Therapy for Transverse Colon Cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 05.02.2024 | ||
| 500 | |a Date Revised 05.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A 77-year-old female patient presented with a medical history of 4 cancerous lesions, each with a surgical history. She was referred to our hospital due to anemia. Upon examination, she was diagnosed with transverse colon cancer. Duodenal invasion was suspected, which made performing R0 surgery difficult; therefore, the NAC approach was chosen. Three courses of CAPOX were administered, resulting in tumor obstruction, leading to the formation of an ileum stoma. MSI testing revealed MSI-H, and pembrolizumab treatment was initiated. CT scans showed tumor shrinkage, and PET scans indicated no accumulation, resulting in a cCR. Colon resection including the lesion suspected of stenosis was performed with a strong desire for stoma closure and the determination of potential curative resection. Additionally, a partial resection of the duodenum was performed. Pathological examination did not reveal any evident tumor cells, leading to the determination for a pCR. The patient has been under postoperative surveillance for 1 year without any recurrence | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a pembrolizumab |2 NLM | |
| 650 | 7 | |a DPT0O3T46P |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 700 | 1 | |a Hirose, Hajime |e verfasserin |4 aut | |
| 700 | 1 | |a Okamura, Shu |e verfasserin |4 aut | |
| 700 | 1 | |a Takeyama, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kawamoto, Risa |e verfasserin |4 aut | |
| 700 | 1 | |a Sawamura, Narumi |e verfasserin |4 aut | |
| 700 | 1 | |a Sakai, Satomi |e verfasserin |4 aut | |
| 700 | 1 | |a Hashizume, Sakina |e verfasserin |4 aut | |
| 700 | 1 | |a Koh, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hayashi, Koji |e verfasserin |4 aut | |
| 700 | 1 | |a Hara, Akio |e verfasserin |4 aut | |
| 700 | 1 | |a Katsura, Yoshiteru |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshioka, Setsuko |e verfasserin |4 aut | |
| 700 | 1 | |a Ebisui, Chikara |e verfasserin |4 aut | |
| 700 | 1 | |a Yano, Masahiko |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gan to kagaku ryoho. Cancer & chemotherapy |d 1993 |g 50(2023), 13 vom: 02. Dez., Seite 1612-1614 |w (DE-627)NLM012601861 |x 0385-0684 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2023 |g number:13 |g day:02 |g month:12 |g pages:1612-1614 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2023 |e 13 |b 02 |c 12 |h 1612-1614 | ||